Skip to main content

Table 1 Comparison of baseline characteristics (ITT analysis set)

From: Cerebrolysin combined with rehabilitation promotes motor recovery in patients with severe motor impairment after stroke

Demographic parameter

Cerebrolysin (n = 34)

Placebo (n = 32)

Male sex: N (%)

29 (82.9)

24 (72.7)

Mean age: years (SD)

64.7 (10.1)

63.0 (10.6)

Mean weight: kg (SD)

65.4 (11.3)

66.7 (12.7)

Mean height: cm (SD)

165.7 (8.6)

165.7 (9.6)

Prevalence of risk factors: N (%)

  

 Hypertension

20 (57.1)

11 (33.3)

 Hyperlipidemia

1 (2.9)

4 (12.1)

 Diabetes mellitus

10 (28.6)

9 (27.3)

 Arrhythmia

3 (8.6)

0 (0.0)

 Coronary artery disease

3 (8.6)

4 (12.1)

Stroke side: N (%), Rt : Lt

14 (41.2) : 20 (58.8)

20 (62.5) : 12 (37.5)

Stroke etiology: N (%)

  

 Large artery atherosclerosis

13 (38.2)

11 (34.4)

 Small vessel occlusion

10 (29.4)

14 (43.8)

 Cardioembolism

7 (20.6)

4 (12.5)

 Other determined

1 (2.9)

1 (3.1)

 Undetermined ischemic stroke

3 (8.8)

2 (6.3)

Stroke lesion: N, cortical : subcortical : cortical-subcortical)

7: 6 : 21

8: 3 : 22

Stroke lesion characteristics

  

 Cortex

7

8

 Cortex/BG/IC

3

0

 Cortex/BG/IC/Corona radiata

3

1

 Cortex/Corona radiata

0

2

 BG/IC

9

14

 BG/IC/Corona radiata

3

3

 Corona radiata

8

3

 Thalamus

1

2

Initial stroke treatment: N

  

 Intravenous thrombolysis

5

3

 Intraarterial thrombolysis

1

2

 Intraarterial thrombectomy

2

2

Baseline stroke severity: Mean (SD)

  

 NIHSS

8.4 (5.8)

7.0 (4.9)

 Lesion volumes: cm3

15.560 (27.023)

19.253 (18.846)

 Total FMA

42.0 (24.2)

42.2 (28.5)

 Upper limb of FMA

24.6 (18.8)

26.7 (20.7)

 Lower limb of FMA

17.4 (9.5)

15.5 (10.0)

  1. ITT intention-to-treat, BG basal ganglia, IC internal capsule, NIHSS National Institutes of Health Stroke Scale, FMA Fugl-Meyer assessment